综述:接受免疫抑制治疗的炎症性肠病患者中的潜伏性结核——风险、筛查、诊断与管理
全球约四分之一人口有潜伏性结核感染(LTBI),免疫抑制是LTBI再激活和活动性结核的风险因素。本文综述炎症性肠病(IBD)患者LTBI的筛查、诊断与治疗,由感染病和IBD专家综合建议:应主动筛查(评估危险因素、干扰素γ释放试验或结核菌素皮肤试验及胸部X线),治疗需视情况而定,理想情况在免疫抑制前进行,但紧急需要IBD治疗时可同时进行,最好由多学科团队指导。
要点
- IBD患者接受免疫抑制治疗前应主动筛查LTBI,包括危险因素评估、干扰素γ释放试验或结核菌素皮肤试验及胸部X线。
- LTBI治疗应视情况而定,理想情况在免疫抑制前进行,紧急需要IBD治疗时可同时进行。
- 管理最好由胃肠病学家、感染病专家和药师组成的多学科团队指导,治疗期间建议持续监测。
核心结论
- 对接受免疫抑制治疗的IBD患者,主动筛查LTBI至关重要,且有多种治疗策略可用。
- 报告真实世界经验对于完善当前管理建议至关重要。
研究设计与样本
- 综述已发表文献,由感染病和IBD专家综合筛查与治疗建议。
主要发现
- 全球约四分之一人口有LTBI,系统性免疫抑制是LTBI再激活和活动性结核的风险因素,再激活可导致显著发病和死亡。
- 当前关于IBD患者LTBI检测和治疗的指南零散且证据缺乏。
- LTBI治疗应视情况而定,与地理流行性、旅行等因素相关。
- 较新的LTBI治疗显示希望,但需考虑药物相互作用。
- 证据存在重大空白,特别是针对IBD的特定较新治疗方法。
关键数值与推荐
- 筛查应包括危险因素评估、干扰素γ释放试验或结核菌素皮肤试验及胸部X线。
- 理想情况下LTBI治疗应在免疫抑制前使用,但紧急需要IBD医疗时可同时应用。
- 管理最好由涉及胃肠病学家、感染病专家和药师的多学科团队指导。
- 建议治疗期间持续监测。
临床怎么用
- 对接受免疫抑制治疗的IBD患者应主动筛查LTBI。
- LTBI治疗应视情况而定,理想情况在免疫抑制前进行,紧急需要IBD治疗时可同时进行。
- 管理最好由多学科团队指导,治疗期间建议持续监测。
局限性
- 当前指南零散且证据缺乏。
- 证据存在重大空白,特别是针对IBD的特定较新治疗方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One quarter of the world's population has latent tuberculosis infection (LTBI). Systemic immunosuppression is a risk factor for LTBI reactivation and the development of active tuberculosis. Such reactivation carries a risk of significant morbidity and mortality. Despite the increasing global incidence of inflammatory bowel disease (IBD) and the use of immune-based therapies, current guidelines on the testing and treatment of LTBI in patients with IBD are haphazard with a paucity of evidence. AIM: To review the screening, diagnostic practices and medical management of LTBI in patients with IBD. METHODS: Published literature was reviewed, and recommendations for testing and treatment were synthesised by experts in both infectious diseases and IBD. RESULTS: Screening for LTBI should be performed proactively and includes assessment of risk factors, an interferon-gamma releasing assay or tuberculin skin test and chest X-ray. LTBI treatment in patients with IBD is scenario-dependent, related to geographical endemicity, travel and other factors. Ideally, LTBI therapy should be used prior to immune suppression but can be applied concurrently where urgent IBD medical treatment is required. Management is best directed by a multidisciplinary team involving gastroenterologists, infectious diseases specialists and pharmacists. Ongoing surveillance is recommended during therapy. Newer LTBI therapies show promise, but medication interactions need to be considered. There are major gaps in evidence, particularly with specific newer therapeutic approaches to IBD. CONCLUSIONS: Proactive screening for LTBI is essential in patients with IBD undergoing immune-suppressing therapy and several therapeutic strategies are available. Reporting of real-world experience is essential to refining current management recommendations.
引用
- Fehily SR, Al-Ani AH, Abdelmalak J, et al. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022. PMID: 35596242. doi:10.1111/apt.16952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。